ABSTRACT
Background The WHO has identified the need for a better understanding of which patients can be cured with ultrashort course hepatitis C (HCV) therapy
Methods 202 individuals with chronic HCV were randomised to fixed-duration shortened therapy (8 weeks) vs variable-duration ultrashort strategies (VUS1/2). Participants not cured following first-line treatment were retreated with 12 weeks’ sofosbuvir/ledipasvir/ribavirin. Primary outcome was sustained virological response 12 weeks (SVR12) after first-line treatment and retreatment. Participants were factorially randomised to receive ribavirin with first-line treatment.
Results All evaluable participants achieved SVR12 overall (197/197, 100%[95%CI 98-100]) demonstrating non-inferiority between fixed-duration and variable-duration strategies (difference 0% [95%CI −3.8%,+3.7%], 4% pre-specified non-inferiority margin). First-line SVR12 was 91%[86%-97%] (92/101) for fixed-duration vs 48%[39%-57%] (47/98) for variable-duration, but was significantly higher for VUS2 (72% [56%-87%] (23/32)) than VUS1 (36% [25%-48%] (24/66)). Overall first-line SVR12 was 72%[65%-78%] (70/101) without ribavirin and 68%[61%-76%] (69/98) with ribavirin (p=0.48). At treatment failure, the emergence of viral resistance was lower with ribavirin (12% [2%-30%] (3/26)) than without (38% [21%-58%] (11/29), p=0.01).
Conclusions Unsuccessful first-line short-course therapy did not compromise retreatment with sofosbuvir/ledipasvir/ribavirin (100% SVR12). SVR12 rates were significantly increased when ultrashort treatment varied between 4-7 weeks rather than 4-6 weeks. Ribavirin significantly reduced resistance emergence in those failing first-line therapy.
Registration ISRCTN 37915093.
Funding National Institutes of Health Research.
Competing Interest Statement
GC has received fees from MSD and Gilead unrelated to this work. SR has carried out consultancy work for Gilead SM has received fees from Abbvie, MSD and Gilead unrelated to this work. SLP has received grants from Gilead Sciences and ViiV Healthcare unrelated to this work. DF has received research funding from Gilead and advised and/or spoken for Gilead, Merck and Abbvie unrelated to this work. RG reports grants from abbvie and Gilead unrelated to this work. MN, SMcP and MW report personal fees from MSD, abbvie and Gilead unrelated to this work. SBarclay reports personal fees from abbvie and Gilead unrelated to this work. SBhagani reports personal fees from abbive, Gilead and MSD. All other authors report no conflicts of interest.
Clinical Trial
ISRCTN:37915093, EUDRACT: 2015-005004-28, CTA 19174/0370/001-0001
Funding Statement
STOP-HCV-1 was funded by the National Institutes of Health Research Efficacy Mechanism Evaluation programme (Project number 14/02/17). Virological analysis was supported by MRC Stratified Medicine Consortium (MR/K01532X/1 STOP-HCV Consortium) and core funding to the Wellcome Trust Centre for Human Genetics provided by the Wellcome Trust (090532/Z/09/Z). The MRC Clinical Trials Unit at UCL is supported by funding from the MRC (MC_UU_12023/22). ASW is an NIHR Senior Investigator. GC is supported in part by the BRC of Imperial College NHS Trust and is an NIHR Research Professor. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by the Cambridgeshire South Research Ethics Committee (15/EE/0435)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Please see supplementary section for full list of investigators
Data Availability
Data sets related to this trial are available on application to the STOPHCV trial management committee
